Modality
Degrader
MOA
CDK4/6i
Target
WRN
Pathway
Proteasome
HS
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
Apr 2017
→ May 2028
Phase 1Current
NCT07002261
337 pts·HS
2025-01→2026-07·Recruiting
NCT05982855
2,760 pts·HS
2017-04→2028-05·Not yet recruiting
3,097 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-07-153mo awayInterim· HS
2028-05-242.1y awayInterim· HS
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1
Not yet…
P1
Recruit…
Catalysts
Interim
2026-07-15 · 3mo away
HS
Interim
2028-05-24 · 2.1y away
HS
RecruitingNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07002261 | Phase 1 | HS | Recruiting | 337 | ORR |
| NCT05982855 | Phase 1 | HS | Not yet recr... | 2760 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| RHH-1969 | Roche | Approved | BET | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN |